Skip to main content

3 Result(s)

within Johanna W. Baars Remove this filter

and

  1. No Access

    Article

    Determination of capillary leakage due to recombinant interleukin-2 by means of noninvasive conductivity measurements

    One of the most common side effects of treatment with recombinant interleukin-2 (IL-2) is capillary leakage. Its genesis is not completely understood. The aim of the study was to determine whether capillary le...

    Cornelis G. Olthof, Johanna W. Baars… in European Journal of Applied Physiology and… (1993)

  2. No Access

    Chapter

    Interleukin-2 toxicity: mechanisms and management

    Interleukin-2 (IL-2) is a glycoprotein produced by activated T cells which is able to induce a response in 15–30% of the patients with metastatic renal cell cancer or melanoma [1–5].

    Johanna W. Baars in The role of interleukin-2 in the treatment of cancer patients (1993)

  3. No Access

    Article

    Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: A pilot study

    Tumour infiltrating lymphocytes (TIL) were isolated and expanded from biopsy samples of 4 patients with metastatic melanoma. The patients were treated with autologous expanded TIL and continuous or bolus infus...

    Johanna W. Baars, Johanna C. M. Fonk, Riekeld J. Scheper… in Biotherapy (1992)